Tiblio
Sign Up

TXG

10X Genomics Inc
NASDAQHEALTHCAREHEALTH INFORMATION SERVICES

Key Statistics

Market Cap
$4.80B
P/E Ratio
—
EPS
$-0.16
Beta
2.04
52W High
$40.56
52W Low
$11.16
50-Day MA
$28.13
200-Day MA
$20.39
Dividend Yield
—
Profit Margin
-3.55%
Forward P/E
666.67
PEG Ratio
—

About 10X Genomics Inc

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and Asia Pacific. The company is headquartered in Pleasanton, California.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)$638.78M
Gross Profit (TTM)$445.11M
EBITDA$-30.67M
Operating Margin-11.30%
Return on Equity-2.98%
Return on Assets-4.48%
Revenue/Share (TTM)$5.06
Book Value$6.24
Price-to-Book6.08
Price-to-Sales (TTM)7.52
EV/Revenue7.04
EV/EBITDA119.88
Quarterly Earnings Growth (YoY)0.00%
Quarterly Revenue Growth (YoY)-2.60%
Shares Outstanding$116.88M
Float$114.82M
% Insiders1.67%
% Institutions111.88%

Historical Volatility

HV 10-Day
56.10%
HV 20-Day
71.23%
HV 30-Day
73.78%
HV 60-Day
69.72%
HV Rank
76.2%

Volatility is currently contracting

Analyst Ratings

Consensus ($29.31 target)
1
Strong Buy
5
Buy
10
Hold

Latest News

10x Genomics and Cleveland Clinic Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies in Patients with Bladder Cancer

Collaboration aims to identify biomarkers predictive of antibody-drug conjugate (ADC) treatment response using 10x's single cell and spatial platforms PLEASANTON, Calif., June 17, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced a research collaboration with Cleveland Clinic, a nonprofit multispecialty academic medical center that integrates clinical care with research and education, to advance research in novel diagnostics for bladder cancer.

PRNewsWire6/17/2026Neutral
10x Genomics Acquires Proteintech Genomics, a Division Within Proteintech Group

Acquisition Expands 10x Genomics' Capabilities in Proteomics PLEASANTON, Calif., June 9, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced the acquisition of Proteintech Genomics, a division within Proteintech Group, a company specializing in developing high-plex proteomic solutions for single cell and spatial applications on 10x platforms.

PRNewsWire6/9/2026Neutral
10x Genomics Q1 Earnings Call Highlights

10x Genomics NASDAQ: TXG reported a first-quarter revenue increase excluding prior-year settlement revenue and used its earnings call to emphasize the launch of Atera, a new spatial biology instrument platform that management described as the most significant product introduction in the company's history.

MarketBeat5/9/2026Positive

More HEALTHCARE Stocks

LLYEli Lilly and CompanyJNJJohnson & JohnsonABBVAbbVie IncUNHUnitedHealth Group IncorporatedMRKMerck & Company IncNVSNovartis AG ADRAZNAstraZeneca PLCNVONovo Nordisk A/SAMGNAmgen IncTMOThermo Fisher Scientific IncGILDGilead Sciences IncABTAbbott Laboratories
View all HEALTHCARE stocks →
Data last updated: 7/9/2026